Home > Back to Publisher > Report Information
|
|
| Countries covered: Global This report analyzes the worldwide markets for Antidepressants in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 45 companies including many key and niche players worldwide such as AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Co., Forest Laboratories, GlaxoSmithKline PLC, H. Lundbeck A/S, Merck & Co., Novartis AG, Organon International, Inc., Pfizer, Inc., Solvay SA, and Wyeth Pharmaceuticals. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Titles available via "online download" are not affected by this and are still delivered to your reading room immediately. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. |
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- II. EXECUTIVE SUMMARY
- 1. Industry Overview
- Market Highlights
- Current and Future Analysis
- Industry Dynamics and Changing Scenario
- Intense Competition in the Antidepressants Marketplace
- Global Antidepressants Market (2004): Major Products in the Pipeline
- Table 1: Leading Brands in the Global Antidepressants Market (2001 & 2002): Sales in US$ Million for Seroxat/Paxil, Zoloft, Effexor, Cipramil/Celexa, Wellbutrin, Prozac, Remeron, Fluoxetine Par, Serzone, and Fluoxetine Barr (include corresponding Graphs/Chart)
- Table 2: Leading Drugs in the Global Antidepressants Market (2003): Sales in US$ Million for Seroxat, Zoloft, Effexor, Cipramil/Celexa, Wellbutrin, Cipralex/Lexapro, Prozac, and Remeron (include corresponding Graphs/Chart)
- SSRI/SNRI Brands in the Global Antidepressants Market (2002-2006): Sales in US$ Million by Geographic Region for Cipralex/Lexapro, Effexor, Cipramil/Celexa, Paxil, Zoloft, and Cymbalta
- SSRIs Garnering Major Share of the Market
- Table 3: Leading Brands in the Global SSRI Antidepressants Market (2003): Percentage Breakdown of Value Sales for Zoloft, Paxil and Paxil CR, Generic Fluoxetine, Celexa, Lexapro, Prozac, Prozac Weekly, and Others (include corresponding Graphs/Chart)
- Emerging Antidepressant Classes Pose Threat to SSRI
- Market Snapshots
- 2. Market Trends & Issues
- New Drugs Making Way into the Market
- Prozac Patent Expiry Opens Door for Generic Versions
- Generic Antidepressants to Hit Market Soon
- TCA Antidepressants Still in Use
- Improved Marketing Spurs Growth
- Westerners Fight Depression Blues; Americans Top the List
- Antidepressants High in Demand but Fail to Satisfy Consumers
- No One is Immune: Not Even Animals!
- Patent Expiry Disturbs Antidepressants Producers
- Unlicensed Antidepressants Pose Danger to Youth Safety
- Global Antidepressants Market (2003): Regulations Governing Select Antidepressants Use in Children
- Growing Safety Concerns-Antidepressants Under Fire
- The Debate Flares
- Are Antidepressants Totally Safe? A Moot but Important Question
- Manufacturers Vociferous in their Protests
- No Satisfactory Answers Yet-The Wait Grows Longer
- Global Antidepressants Market: Drug Regulation for Kids in Britain and the United States
- 3. Depression: A Mental Review
- What is depression?
- Symptoms of Depression
- Causes of Depression
- Types of Depression and Related Disorders
- Major Depressive Disorders (Major Depression)
- Dysthymic Disorder (Minor Depression)
- Bipolar Disorder
- Related Disorder Types
- Seasonal Affective Disorder
- Premenstrual Dysphoric Disorder (PMDD)
- Anxiety Disorders
- Obsessive Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Treatment of Depression
- Options Available in Depression Treatment
- Psychotherapy or Psychiatric Consultation
- Pharmacotherapy
- Combination of Psychotherapy and Pharmacotherapy
- Herbal and Nutritional Treatment
- Exercise
- How Can Depression Treatment become More Effective?
- Global Antidepressants Market: Favorable Drugs Under Specific Conditions
- Global Antidepressants Market: Unfavorable Drugs Under Specific Conditions
- Treatment-Resistant Depression (TRD)
- Optimizing the Dosage
- Switching of Medications
- Combination therapy
- Augmentation Therapy
- Electroconvulsive Therapy
- Facts and Figures on Depression
- Table 4: Global Antidepressants Market (2004): Percentage Breakdown of Prevalence Rate by Disorder Type-Depression, Anxiety, Obsessive Compulsive Disorder, Sleep Disorder, Panic Disorder, Phobias, and Others (include corresponding Graphs/Chart)
- Depression Hits the Elderly Hard
- Men Vs Women-Who is More Depression Prone?
- Depression and Smoking-Interlinked to One Another
- 4. Product Analysis
- What are Antidepressants? A Clear Understanding
- Global Antidepressants Market (2004): Select Brands and their Manufacturers
- Application Areas
- Select Antidepressants and their Applications
- Types of Antidepressants
- Tricyclic Antidepressants (TCAs)
- Global Antidepressants Market: TCA Brands and Dosage Types-Starting Dosage and Normal Dosage
- Global Antidepressants Market: TCAs and their Side Effects
- Monamine Oxidase Inhibitors (MAOIs)
- Global Antidepressants Market: MAOI Brands and Dosage Types-Starting Dosage and Normal Dosage
- Side Effects of Different MAOIs-Tranylcypromine; Isocarboxazid and Phenelzine
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Global Antidepressants Market: SSRIs Brands and Related Dosage-Starting Dosage and Normal Dosage
- Pharmacology
- FDA Approval
- Fluoxetine (Proxac)
- Citalopram
- Fluvoxamine (Luvox)
- Paroxetine
- Sertraline (Zoloft)
- Escitalopram
- Side Effects
- Global Antidepressants Market: Different SSRI Drugs and their Side Effects
- Applications
- Global Antidepressants Market: SSRIs’ Off-Label Application Areas and Medication
- New Generation Antidepressants
- Dopamine-Reuptake Blocking Compounds
- Bupropion
- Serotonin and Noradrenaline Reuptake Inhibitors
- Venlafaxine
- 5HT2 Receptor Antagonist Properties
- Nefazodone
- Trazodone
- Noradrenergic Antagonist
- Mirtazapine
- Global Antidepressants Market: New Generation Drugs and Dosage Types-Starting Dosage and Normal Dosage
- Global Antidepressants Market: New Generation Antidepressants and their Side Effects
- Global Antidepressants Market: Major Drugs by Class-SSRI, SNRI, MAOI, and NaSSA
- 5. Antidepressants: An In-Depth Analysis
- Tracing the Line of History
- Antidepressants, a Mere Accidental Discovery
- Limited Choices and High Risk Rates
- Better Alternatives and Wider Choice-The New Mantra
- Global Antidepressants Market: Launch of Drug Types-TCAs, MAOI, SSRI, and New Generation Variants by Original Version, Secondary Version, and Generic Version
- Adverse Effects of Antidepressants and their Management
- Sedation
- Orthostatic Hypotension
- Insomnia
- Anticholinergic Effects
- Weight Gain/Loss
- Sexual Dysfunction
- Side Effects Associated with Overdose
- Choosing an Antidepressant
- Table 5: Global Antidepressants Market: Percentage Breakdown of Volume Drug Consumption by Disorder Type-Depression, Generalized Anxiety Disorder, Post Traumatic Stress Disorder, Panic Disorder and Others (include corresponding Graphs/Chart)
- Switching Antidepressants
- Do Antidepressants Treat Depression Completely?
- Are Antidepressants Addictive?
- Global Antidepressants Market: Withdrawal Symptoms by Drug Types-TCAs and SSRIs
- Disorders and Antidepressants
- Bipolar Disorder
- Anxiety Disorder
- Panic Disorder
- Antidepressants Used for Treatment of Panic Disorders, their Efficacy/Recommendations, and Side Effects
- A Note of Caution for Panic Patients Using Antidepressants
- Generalized Anxiety Disorder
- SNRI
- SSRI
- TCAs
- Antidepressants Used for Treatment of Anxiety Disorders
- Antidepressants: Causes For and Against
- Cause for Antidepressants:
- Antidepressants Effective in Curing Premenstrual Dysphoric Disorder
- Antidepressants Offer Solution for Itching and Scratching
- Antidepressants Offer Hope for Autistic Children
- Antidepressants Minimize Hot Flushes and Night Sweats
- Antidepressants’ Positive Effect on the Brain
- Longer Duration Antidepressants Treatment Prevents Relapse
- Antidepressants-A New Option for Sleep Apnea
- SSRI Antidepressants May Prove Helpful in Cancer Treatment
- Antidepressants Relaxes Tremors
- Lesser Fear of Breast Cancer with Antidepressants
- Antidepressants for Reducing Chronic Back Pain
- Causes Against Antidepressants
- Greater Heart at Risk with Antidepressants
- Antidepressants Dissipates Sexual Drive
- Hip Fractures Troubles Aged Patients
- Antidepressants can be a Deadly Prescription for Kids
- Dental Problems with Antidepressants
- Facts/Myths About Antidepressants
- Are Pregnant Women at Risk from Antidepressants?
- Is Breast Feeding Safe While on Antidepressants?
- Homeopathic Treatment Versus Antidepressants Treatment-Which is Better?
- Recent Findings on Antidepressants
- 6. Technological Developments
- Monitoring Technology Foresees Antidepressants Effect
- Vagus Nerve Stimulation-Device for Treating Depression
- Global Antidepressants Market: FDA Approvals (2002-2004)
- 7. Product Introductions/Innovations
- GlaxoSmithKline Re-Introduces Paxil CR in US Market
- Ratiopharm Launches Ratio-Paroxetine in Canada
- Organon Introduces Zispin SolTab
- Apotex Releases Generic Version of Paxil
- GlaxoSmithKline Launches Paxil CR
- Lundbeck Launches Lexapro
- 8. Recent Industry Activity
- Pfizer Acquires Esperion
- Organon in Marketing Agreement with STADA
- Andrx Signs Marketing Agreement with Impax and Teva
- GlaxoSmithKline Collaborates with NeuroSearch
- Lundbeck in Marketing Accord with Janssen-Cilag
- Lundbeck Allies with Abbott Laboratories
- Myriad Signs an Agreement with Abbott Laboratories
- Recordati Obtains Marketing Rights from H Lundbeck
- 9. Focus on Select Global Players
- AstraZeneca Plc (UK)
- Bristol-Myers Squibb (USA)
- Eli Lilly and Co. (USA)
- Forest Laboratories (USA)
- GlaxoSmithKline Plc (UK)
- H. Lundbeck A/S (Denmark)
- Merck & Co. (USA)
- Novartis AG (Switzerland)
- Organon International, Inc. (USA)
- Pfizer, Inc. (USA)
- Solvay SA (Brussels)
- Wyeth Pharmaceuticals (USA)
- 10. Global Market Perspective
- Table 6: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region-USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- Table 7: World 10-Year Perspective for Antidepressants by Geographic Region-Percentage Breakdown of Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart)
- III. MARKET
- 1. The United States
- A. Market Analysis
- Current and Future Analysis
- Market Overview
- Antidepressants Usage in the United States
- US Antidepressants Market: Drug Usage
- Competitive Scenario
- Table 8:Leading Players in the US Antidepressants Market (2004 & 2005(E)): Percentage Breakdown of Value Sales for Forest Labs, GlaxoSmithKline, Pfizer, Wyeth, Eli Lilly and Others (include corresponding Graphs/Chart)
- Table 9: Leading Players in the US SSRI/SNRI Market (2004 & 2005(E)): Percentage Breakdown of Value Sales for Forest Labs, Pfizer, Wyeth, GlaxoSmithKline, Eli Lilly and Others (include corresponding Graphs/Chart)
- Trends and Issues
- Are Americans Getting Too Depressed?
- New Drugs Set to Conquer the Market
- Table 10: Leading SSRI/SNRI Brands in the US Antidepressants Market (2000-2005(E)): Percentage Breakdown of Sales for Prozac, Paxil, Zoloft, Celexa, Lexapro, Effexor and Others (include corresponding Graphs/Chart)
- Table 11: US Antidepressants Market (2000-2003): Number of SSRI/SNRI Prescriptions Dispensed in Millions (include corresponding Graphs/Chart)
- Table 12: US Antidepressants Market (2000): Advertising Expenditure in US$ Million on Select SSRIs-Celexa (Citalopram), Prozac (Fluoxetine), Effexor XR (Venlafaxine), Zoloft (Sertraline), Paxil (Paroxetine), and Luvox (Fluvoxamine) (include corresponding Graphs/Chart)
- Depression More Common Among Gays
- FDA Inspects Suicidal Tendencies in Kids on Antidepressants
- FDA Imposes "black-box" Warning
- Generic Drugs Pose Competition to Branded Drugs
- Table 13: Leading SSRI Brands in the US Antidepressants Market (2001): Sales in US$ Million for Zoloft, Paxil, Prozac & Sarafem, Celexa, and Luvox (include corresponding Graphs/Chart)
- Depression Drugs Being Used for Symptoms Other Than Depression
- US Antidepressants Market: Drugs Approved for Different Indications
- Frequent Patent Expiries-A Cause of Concern for Manufacturers
- Patent Expiry of Select Antidepressant Brands in the United States
- Product Launches/Developments
- Strategic Corporate Developments
- Key Players
- Bristol-Myers Squibb
- Eli Lilly and Co.
- Forest Laboratories
- Merck & Co.
- Organon International, Inc.
- Pfizer, Inc.
- Wyeth Pharmaceuticals
- B. Market Analytics
- Table 14: US Recent Past, Current & Future Analysis for Antidepressants by Product Segment-SSRI, New Generation, TCA and MAOI Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- Table 15: US 10-Year Perspective for Antidepressants by Product Segment-Percentage Breakdown of Dollar Sales for SSRI, New Generation, TCA and MAOI for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart)
- 2. Canada
- A. Market Analysis
- Current and Future Analysis
- Market Overview
- Increasing Use of Antidepressants among Canadian Women
- Antidepressants Market-A Recent Past Perspective
- Table 16: Canadian Antidepressants Market (2001): Percentage Breakdown of Value Sales by Class-SSRI, TCAs, MOAI, and Others (include corresponding Graphs/Chart)
- Generic Serzone Recalled from Canadian Market in 2003
- Warning Against Antidepressants Use in Under-18 Age Group
- Product Launch
- B. Market Analytics
- Table 17: Canadian Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 3. Japan
- A. Market Analysis
- Current and Future Analysis
- Recent Past Perspective
- Table 18: CNS Market in Japan (2001): Sales in US$ Million by Drug Class-Antidepressants, Antiulcerants, Cholesterol Reducers, Broad Antibiotic, Antiarrhythmic, Antihypertensive, Narcotic painkiller, Oral Diabetes, Oral Antihistamine, and Antiseizure (include corresponding Graphs/Chart)
- Competitive Scenario
- Table 19: Leading Brands in the Japanese Antidepressants Market (2001 & 2002): Percentage Breakdown of Value Sales for Paxil, Luvox, Depromel, Ludiomil, Toledomin, Toledomin-Jansen, Anafranil, Tetramide, and Others (include corresponding Graphs/Chart)
- A Historical Perspective
- Antidepressants Market in Japan-Major Drug Launches the Period 1973-2000
- B. Market Analytics
- Table 20: Japanese Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 4. Europe
- A. Market Analysis
- Current and Future Analysis
- Market Overview
- Table 21: Leading Players in the European Antidepressants Market (2004 & 2005(E))-Percentage Breakdown of Value Sales for GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Wyeth and Others (include corresponding Graphs/Chart)
- Changes in European Patent Litigation
- Strategic Corporate Developments
- B. Market Analytics
- Table 22: European Recent Past, Current & Future Analysis for Antidepressants by Geographic Region-France, Germany, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- Table 23: European 10-Year Perspective for Antidepressants by Geographic Region-Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, and Rest of Europe Markets for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart)
- 4A. France
- Market Analysis
- Current and Future Analysis
- Table 24: French Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 4B. Germany
- Market Analysis
- Current and Future Analysis
- Table 25: German Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 4c. The United Kingdom
- A. Market Analysis
- Current and Future Analysis
- Market Overview
- A Recent Past Perspective
- UK Bans Antidepressant Use in Children (2003)
- Table 26: Antidepressants Market in the UK (1993-2000): Number of Associated Deaths in England and Wales by Drug Class-TCAs, MAOIs, SSRIs and Others (include corresponding Graphs/Chart)
- Prescriptions and Expenditure Statistics
- Regional Analysis-Scotland
- Antidepressants, a Happy Pill for Sad Scots
- Key Players
- AstraZeneca
- GlaxoSmithKline
- B. Market Analytics
- Table 27: UK Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 4d. Italy
- Market Analysis
- Current and Future Analysis
- Table 28: Italian Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 4e. Spain
- Market Analysis
- Current and Future Analysis
- Table 29: Spanish Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 4f. Rest of Europe
- A. Market Analysis
- Current and Future Analysis
- Focus on Select Regional Markets
- Denmark
- Danish People Display Greater Preference for Antidepressants
- Finland
- Antidepressants Consumption Increases Among Young Adults
- Key Players
- H. Lundbeck A/S (Denmark)
- Novartis AG (Switzerland)
- Solvay SA (Brussels)
- B. Market Analytics
- Table 30: Rest of Europe Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010
- corresponding Graphs/Chart)
- 5. Asia-Pacific
- A. Market Analysis
- Current and Future Analysis
- Australia
- A Recent Past Market Perspective
- Commonly Used Antidepressants in Australia (2001)
- Strategic Corporate Development
- B. Market Analytics
- Table 31: Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- 6. Latin America
- A. Market Analysis
- Current and Future Analysis
- Chile
- High Usage of Antidepressants among Chileans
- Strategic Corporate Development
- B. Market Analytics
- Table 32: Latin America Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart)
- IV. COMPETITION
- 1. Abbott Laboratories (USA)
- Table 33: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)
- Table 34: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)
- Table 35: Quarterly Sales Analysis: 2003-2004 (In US$ million)
- Table 36: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)
- Table 37: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million)
- Abbott India Ltd. (India)
- 2. Akzo Nobel NV (The Netherlands)
- Table 38: First Quarter Sales Analysis: 2004-2005 (Q1) (In € million)
- Table 39: First Quarter Sales Analysis by Segment: 2004-2005 (Q1) (In € million)
- Table 40: Annual Sales Analysis: 2002-2004 (In € million)
- Table 41: Annual Sales Analysis by Segment: 2003-2004 (In € million)
- Table 42: Annual Sales Analysis by Region: 2003-2004 (In € million)
- Organon NV (The Netherlands)
- Organon International, Inc. (USA)
- Organon Laboratories Ltd. (UK)
- 3. Andrx Corporation (USA)
- Table 43: First Quarter Sales Analysis: 2004-2005 (Q1) (In US$ million)
- Table 44: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 45: Quarterly Sales Analysis: 2003-2004 (In US$ million)
- 4. Apotex, Inc. (Canada)
- 5. AstraZeneca PLC (UK)
- Table 46: First Quarter Sales Analysis: 2004-2005 (Q1) (In US$ billion)
- Table 47: First Quarter Sales Analysis by Geographic Region: 2004-2005 (Q1) (In US$ billion)
- Table 48: Annual Sales Analysis: 2003-2004 (In US$ billion)
- Table 49: Annual Sales Analysis by Therapy Area: 2003-2004 (In US$ billion)
- Table 50: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ billion)
- Astrazeneca Pharmaceuticals LP (USA)
- 6. Barr Laboratories, Inc. (USA)
- Table 51: Nine Months Sales Analysis: 2004-2005 (Nine months Ended, March) (In US$ million)
- Table 52: Nine Months Sales Analysis by Product: 2004-2005 (Nine Months Ended, March) (In US$ million)
- Table 53: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 54: Annual Sales Analysis by Product: 2003-2004 (In US$ million)
- 7. Boehringer Ingelheim GmbH (Germany)
- Table 55: Annual Sales Analysis: 2003-2004 (In € million)
- Table 56: Annual Sales Analysis by Product Segment: 2003-2004 (In € million)
- Table 57: Annual Sales Analysis by Region: 2003-2004 (In € million)
- 8. Bristol-Myers Squibb Co. (USA)
- Table 58: Annual Sales Analysis: 2003-2004 (In US$ billion)
- Table 59: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion)
- Table 60: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ billion)
- 9. Cortex Pharmaceuticals, Inc. (USA)
- 10. Dr. Reddy's Laboratories Ltd. (India)
- Table 61: Annual Sales Analysis: 2003-2005 (In INR million)
- Table 62: Annual Sales Analysis by Product Segment: 2003-2004 (In INR million)
- Table 63: Annual Sales Analysis by Geographical Region: 2003-2004 (In INR million)
- 11. Eli Lilly and Company (USA)
- Table 64: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)
- Table 65: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)
- Table 66: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million)
- Table 67: Annual Sales Analysis: 2002-2004 (In US$ million)
- Table 68: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)
- Table 69: Annual Sales Analysis by Product: 2003-2004 (In US$ million)
- Table 70: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million)
- Table 71: Quarterly Sales Analysis: 2003-2004 (In US$ million)
- Eli Lilly And Company Limited (UK)
- Eli Lilly Canada, Inc. (Canada)
- Lilly Deutschland GmbH (Germany)
- 12. Eon Labs, Inc. (USA)
- Table 72: First Quarter Sales Analysis: 2004-2005 (Q1) (In US$ million)
- Table 73: Annual Sales Analysis: 2002-2004 (In US$ million)
- Table 74: Quarterly Sales Analysis: 2003-2004 (In US$ million)
- 13. F. Hoffmann-La Roche Ltd. (Switzerland)
- Table 75: Half Yearly Sales Analysis: 2004-2005 (H1) (In CHF million)
- Table 76: Annual Sales Analysis: 2003-2004 (In CHF million)
- Table 77: Annual Sales Analysis by Division: 2003-2004 (In CHF millions)
- 14. Forest Laboratories, Inc. (USA)
- Table 78: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ billion)
- Table 79: Annual Sales Analysis: 2004-2005 (In US$ billion)
- Table 80: Quarterly Sales Analysis: 2004-2005 (In US$ billion)
- Table 81: Annual Sales Analysis by Geographical Region: 2004-2005 (In US$ billion)
- Table 82: Quarterly Sales Analysis: 2003-2004 (In US$ billion)
- Table 83: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ billion)
- Forest Pharmaceuticals, Inc. (USA)
- 15. GlaxoSmithKline PLC (UK)
- Table 84: Half Yearly Sales Analysis: 2004-2005 (H1) (In £ million)
- Table 85: Half Yearly Sales Analysis by Division: 2004-2005 (H1) (In £ million)
- Table 86: Annual Sales Analysis: 2003-2004 (In £ million)
- Table 87: Annual Sales Analysis by Division: 2003-2004 (In £ million)
- GlaxoSmithKline PLC (UK)
- GlaxoSmithKline PLC (UK)
- Glaxo Smithkline Canada, Inc. (Canada)
- 16. H. Lundbeck A/S (Denmark)
- Table 88: Annual Sales Analysis: 2002-2004 (In DKK billion)
- Table 89: Annual Sales Analysis by Geographical Region: 2003-2004 (In DKK billion)
- 17. Impax Laboratories, Inc. (USA)
- 18. Johnson & Johnson (USA)
- Table 90: First Quarter Sales Analysis: 2004-2005 (Q1) (In US$ billion)
- Table 91: First Quarter Sales Analysis by Segment: 2004-2005 (Q1) (In US$ billion)
- Table 92: First Quarter Sales Analysis by Geographical Region: 2004-2005 (Q1) (In US$ billion)
- Table 93: Annual Sales Analysis: 2003-2004 (In US$ billion)
- Table 94: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion)
- Table 95: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ billion)
- Table 96: Annual Sales Analysis by Quarter: 2003-2004 (In US$ billion)
- 19. Janssen-Cilag International NV (Belgium)
- 20. Juvantia Pharma (Finland)
- 21. Meiji Seika Kaisha Ltd. (Japan)
- Table 97: Annual Sales Analysis: 2003-2004 (In ¥ million)
- Table 98: Annual Sales Analysis by Business Segment: 2003-2004 (In ¥ million)
- 22. Merck & Co., Inc. (USA)
- Table 99: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 100: Annual Sales Analysis by Segment: 2003-2004 (In US$ Million)
- Table 101: Quarterly Sales Analysis: 2003-2004 (In US$ Million)
- 23. Mylan Laboratories, Inc. (USA)
- Table 102: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)
- Table 103: Annual Sales Analysis: 2003-2005 (In US$ million)
- Table 104: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)
- Table 105: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
- Table 106: Quarterly Sales Analysis: 2004-2005 (In US$ million)
- 24. Myriad Genetics, Inc. (USA)
- Table 107: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 108: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)
- 25. Neurosearch A/S (Denmark)
- 26. Novartis AG (Switzerland)
- Table 109: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion)
- Table 110: Annual Sales Analysis: 2002-2004 (In US$ billion)
- Table 111: Annual Sales Analysis by Division: 2003-2004 (In US$ billion)
- Table 112: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ billion)
- Table 113: Quarterly Sales Analysis: 2003-2004 (In US$ billion)
- Sandoz, Inc. (Austria)
- Sandoz Deutschland GmbH (Germany)
- 27. Olympian Labs (USA)
- 28. Orion Corporation (Finland)
- Table 114: Annual Sales Analysis: 2003-2004 (In € billion)
- 29. Paddock Laboratories, Inc. (USA)
- 30. Par Pharmaceutical, Inc. (USA)
- Table 115: First Quarter Sales Analysis: 2004-2005 (Q1) (In US$ million)
- Table 116: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 117: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million)
- 31. Pfizer, Inc. (USA)
- Table 118: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion)
- Table 119: Annual Sales Analysis: 2003-2004 (In US$ billion)
- Table 120: Annual Sales Analysis by Business Segment: 2003-2004 (In US$ billion)
- Table 121: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ billion)
- Pfizer Australia Pty., Ltd. (Australia)
- Pfizer Canada, Inc. (Canada)
- Pfizer GmbH (Germany)
- Pfizer Limited (UK)
- 32. Ranbaxy Pharmaceuticals, Inc. (USA)
- 33. Ratiopharm (Canada)
- 34. Recordati SpA (Italy)
- Table 122: Half-Yearly Sales Analysis: 2004-2005 (H1) (In € million)
- Table 123: Annual Sales Analysis: 2003-2004 (In € million)
- Table 124: Annual Sales Analysis by Segment: 2003-2004 (In € million)
- Table 125: Annual Sales Analysis by Geographical Region: 2003-2004 (In € million)
- 35. Sankyo Pharma, Inc. (USA)
- 36. Sanofi-Aventis (France)
- Table 126: Half Yearly Sales Analysis: 2004-2005 (H1) (In € million)
- Table 127: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million)
- Table 128: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In € million)
- Table 129: Annual Sales Analysis: 2003-2004 (In US$ million)
- 37. Servier (France)
- 38. Skyepharma PLC (UK)
- Table 130: Annual Sales Analysis: 2003-2004 (In £ million)
- Table 131: Annual Sales Analysis by Region: 2003-2004 (In £ million)
- 39. Solvay SA (Belgium)
- Table 132: First Quarter Sales Analysis: 2004-2005 (Q1) (In € million)
- Table 133: Annual Sales Analysis: 2003-2004 (In € million)
- Table 134: Annual Sales Analysis by Segment: 2003-2004 (In € million)
- Solvay Pharmaceutical, Inc. (USA)
- 40. STADA Arzneimittel AG (Germany)
- Table 135: First Quarter Sales Analysis: 2004-2005 (Q1) (In € million)
- Table 136: First Quarter Sales Analysis by Segment: 2004-2005 (Q1) (In € million)
- Table 137: Annual Sales Analysis: 2003-2004 (In € million)
- Table 138: Annual Sales Analysis by Segment: 2003-2004 (In € million)
- 41. Strides Arcolab Limited (India)
- 42. Temmler Pharma GmbH & Co. KG (Germany)
- 43. Teva Pharmaceutical Industries Ltd. (Israel)
- Table 139: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ Million)
- Table 140: Half Yearly Sales Analysis by Geographic Region: 2004-2005 (H1) (In US$ Million)
- Table 141: Half Yearly Sales Analysis by Business Segment: 2004-2005 (H1) (In US$ Million)
- Table 142: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ Million)
- Table 143: Annual Sales Analysis by Business Segment: 2003-2004 (In US$ Million)
- 44. Watson Pharmaceuticals, Inc. (USA)
- Table 144: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 145: Annual Sales Analysis by Business Segment: 2003-2004 (In US$ million)
- 45. Wyeth (USA)
- Table 146: Half yearly Sales Analysis: 2004-2005 (H1) (In US$ million)
- Table 147: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)
- Table 148: Annual Sales Analysis: 2003-2004 (In US$ million)
- Table 149: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)
- Table 150: Annual Sales Analysis by Region: 2003-2004 (In US$ million)
- Wyeth Australia Pty., Ltd. (Australia)
- Wyeth Pharmaceuticals (USA)
More Global Behavioral Health Reports
Anxiety Disorders by
Global Industry Analysts
This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest ...
Bipolar Depression Global Clinical Trials Review, Q4, 2010 by
GlobalData
Bipolar Depression Global Clinical Trials Review, Q4, 2010 Summary GlobalData's clinical trial report, “Bipolar Depression Global Global Clinical Trials Review, Q4, 2010""” provides ...
Disease and Therapy Review: Major Depressive Disorder by
Timely Data Resources, Inc.
The Major Depressive Disorder Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major countries ...
Bipolar Disorder by
Global Industry Analysts
This report analyzes the worldwide markets for Bipolar Disorder in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest ...
ADHD Therapeutics by
Global Industry Analysts
This report analyzes the worldwide markets for ADHD Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US and Rest of ...
See all reports like this >>
Related Markets
Behavioral Health Reports
- Key Companies: Depression - Leading players must adapt to remain competitive
- CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players
- Product Profiles: Depression - Next generation vies for second-line patients
- Alcohol Addiction Global Clinical Trials Review, Q2, 2011
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
